Rise Therapeutics is developing a pipeline of Immunobiotic therapies to treat a wide range of clinical indications. Leveraging its discovery capabilities, Rise has identified several unique microbiome-related pathways that potentially have therapeutic relevance. With our strong product development focus, the first two programs for which Rise plans to establish clinical proof-of-concept are focused on autoimmune and inflammatory disease.
R-2487 is Rise Therapeutics' most advanced program that is nearing clinical proof-of-concept studies. Based upon Rise’s core TPX platform technology that allows for delivery oral biological therapies, R-2487 is an Immunobiotic drug that targets a key immunological pathway. R-2487 has the unique ability to induce specific populations of T regulatory cells that have the ability to intervene with inflammatory processes that can cause autoimmunity in tissues distal from the intestinal tract.
R-3750, also based upon Rise Therapeutics’ proprietary TPX platform, is a second Immunobiotic program that is being developed for the treatment of gastrointestinal (GI) inflammatory disease. R-3750 works by inducing immune homeostasis and enhancing the gut barrier, thus, treating the underlying basis of GI-associated inflammatory disease.